Literature DB >> 12954644

Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.

Eddy S Yang1, Kerry L Burnstein.   

Abstract

1,25-(OH)2 vitamin D3 (1,25-(OH)2D3) exerts antiproliferative effects via cell cycle regulation in a variety of tumor cells, including prostate. We have previously shown that in the human prostate cancer cell line LN-CaP, 1,25-(OH)2D3 mediates an increase in cyclin-dependent kinase inhibitor p27Kip1 levels, inhibition of cyclin-dependent kinase 2 (Cdk2) activity, hypophosphorylation of retinoblastoma protein, and accumulation of cells in G1. In this study, we investigated the mechanism whereby 1,25-(OH)2D3 increases p27 levels. 1,25-(OH)2D3 had no effect on p27 mRNA levels or on the regulation of a 3.5-kb fragment of the p27 promoter. The rate of p27 protein synthesis was not affected by 1,25-(OH)2D3 as measured by luciferase activity driven by the 5'- and 3'-untranslated regions of p27 that regulate p27 protein synthesis. Pulse-chase analysis of 35S-labeled p27 revealed an increased p27 protein half-life with 1,25-(OH)2D3 treatment. Because Cdk2-mediated phosphorylation of p27 at Thr187 targets p27 for Skp2-mediated degradation, we examined the phosphorylation status of p27 in 1,25-(OH)2D3-treated cells. 1,25-(OH)2D3 decreased levels of Thr187 phosphorylated p27, consistent with inhibition of Thr187 phosphorylation-dependent p27 degradation. In addition, 1,25-(OH)2D3 reduced Skp2 protein levels in LNCaP cells. Cdk2 is activated in the nucleus by Cdk-activating kinase through Thr160 phosphorylation and by cdc25A phosphatase via Thr14 and Tyr15 dephosphorylation. Interestingly, 1,25-(OH)2D3 decreased nuclear Cdk2 levels as assessed by subcellular fractionation and confocal microscopy. Inhibition of Cdk2 by 1,25-(OH)2D3 may thus involve two mechanisms: 1) reduced nuclear Cdk2 available for cyclin binding and activation and 2) impairment of cyclin E-Cdk2-dependent p27 degradation through cytoplasmic mislocalization of Cdk2. These data suggest that Cdk2 mislocalization is central to the antiproliferative effects of 1,25-(OH)2D3.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954644     DOI: 10.1074/jbc.M306340200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.

Authors:  Lu Ding; Rong Li; Rongxin Sun; Yang Zhou; Yubo Zhou; Xiaoping Han; Yong Cui; Wu Wang; Qing Lv; Jingping Bai
Journal:  Cell Cycle       Date:  2017-08-03       Impact factor: 4.534

2.  1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes.

Authors:  Jian Guo; Zhenhua Ma; Qingyong Ma; Zheng Wu; Ping Fan; Xiaojie Zhou; Lulu Chen; Shuang Zhou; David Goltzman; Dengshun Miao; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health.

Authors:  Tuija Jääskeläinen; Paul Knekt; Jukka Marniemi; Laura Sares-Jäske; Satu Männistö; Markku Heliövaara; Ritva Järvinen
Journal:  Eur J Nutr       Date:  2012-04-27       Impact factor: 5.614

4.  Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells.

Authors:  Yong Xu; Fang Fang; Daret K St Clair; Sajni Josson; Pradoldej Sompol; Ivan Spasojevic; William H St Clair
Journal:  Mol Cancer Ther       Date:  2007-06-29       Impact factor: 6.261

5.  Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status.

Authors:  Sarah Mordan-McCombs; Theodore Brown; Wei-Lin Winnie Wang; Ann-Christin Gaupel; Joellen Welsh; Martin Tenniswood
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-27       Impact factor: 4.292

6.  Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells.

Authors:  Ryoko Okamoto; Remi Delansorne; Naoki Wakimoto; Ngan B Doan; Tadayuki Akagi; Michelle Shen; Quoc H Ho; Jonathan W Said; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2011-08-27       Impact factor: 7.396

Review 7.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

8.  Mechanisms of nuclear vitamin D receptor resistance in Harvey-ras-transfected cells.

Authors:  Laura M Taber; Lynn S Adams; Dorothy Teegarden
Journal:  J Nutr Biochem       Date:  2008-10-01       Impact factor: 6.048

Review 9.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

10.  Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype.

Authors:  Srirupa Roy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert Sclafani; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2008-06-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.